DNA alkylation by duocarmycin payload

Duocarmazine is a synthetic antibody–drug conjugate payload derived from the duocarmycins, a family of extremely potent cytotoxic agents originally found in Streptomyces spp. Duocarmycin and its analogs are not receptors or classical molecular targets, but alkylating agents that exert anticancer effects by highly sequence-selective binding to the minor groove of DNA and alkylating adenine bases at the N3 position, primarily in AT-rich regions. This irreversible DNA alkylation triggers DNA damage responses, leading to cell cycle arrest and apoptosis. When delivered via antibody–drug conjugates such as SYD985 (duocarmazine), this payload is targeted to specific antigens (e.g., HER2), potentially improving the therapeutic window. However, this entity is mechanistic in nature, not a molecular target itself, and its main clinical applications are in the treatment of HER2-positive and other cancers. Note: This entry is considered incorrect as a "target" in the classical sense, as it describes a pharmacological process (DNA alkylation induced by a payload) rather than a discrete, canonical protein or molecular target. The canonical target of duocarmazine-based ADCs is DNA, via minor-groove binding and alkylation.

Other names

duocarmycin-mediated DNA damageduocarmazine-induced DNA alkylationDNA minor-groove alkylation by duocarmycin

DNA minor groove binding and sequence-selective alkylation by duocarmycin payload; Irreversible covalent modification (alkylation) of adenine (N3 position), leading to DNA architecture disruption and tumor cell death